[
    {
        "type": "text",
        "text": "临床研究",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "2型糖尿病合并腰椎骨质疏松的临床相关因素分析 ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "张玉娴，闵少雄",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "南方医科大学珠江医院骨科一区，广东广州510280摘要：目的分析2型糖尿病骨质疏松患者腰椎骨密度(BMD)与年龄、性别、体质量、病程、空腹血糖等因素的相关性。方法收集临床资料完整的2型糖尿病合并骨质疏松患者40例为A组，使用倾向得分匹配法(PSM)确定年龄性别匹配的同期健康体检者40例为B组，两组病例均测定腰椎( $\\mathrm { { \\ L _ { 1 } } \\mathrm { { \\sim } L _ { 4 } } } ,$ 及左侧股骨BMD,并记录性别、年龄、病程、体质量指数、空腹血糖及血钙、血磷、尿钙、尿磷等临床指标进行比较。结果A组L-4腰椎BMD明显低于B组( $P { < } 0 . 0 5 \\$ ;2型糖尿病骨质疏松患者腰椎BMD与性别相关,并与病程呈负相关,而与体质量指数(BMI)、空腹血糖、尿钙、尿磷呈正相关,但与年龄、血钙、血磷无明显相关关系。结论 2型糖尿病患者骨密度降低与性别、BMI、病程延长、血糖控制不佳等因素有关。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "关键词：2型糖尿病;骨质疏松;骨密度",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Analysis of clinical factors correlating with osteoporosis in patients with type 2 diabetes mellitus ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "ZHANG Yuxian,MIN haoxiong DepartmentofOrthopedics,ZhujiangHospital,Southern MedicalUniversity,Guangzhou 50280,hina ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Abstract:Objective Toanalyze theclinical factors thatcontribute to lowered bonemineral density (BMD)of the lumbar vertebrae in type 2 diabetic patients.Methods Forty type2 diabetic patientswith osteoporosis and40 age-and gender-matched healthy individuals，selected using propensity score method, were examined for BMD of the L1 to L4 vertebraeandtheleftfemur. Age,gendercourseofthedisease,body massindex (BM),fasting blood gucose,serumcalcium, serum phosphate,urinarycalcium,and urinary phosphate were compared between the two groups. Results BMDof the L1 to L4 vertebras was significantly lower in the diabetic group than in the healthy individuals $( P { < } 0 . 0 5 )$ . In the diabetic patients, BMD showed an obvious diference between male and female patients and was negatively corelated with the course of the disease but positively withBMI,fasting blood glucose,urinary calcium and urinary phosphate; BMD was not correlated with age,serumcalcium orsrum phosphate in these patients.Conclusion Osteoporosis intype2diabetic patients iscloselyrelated with gender, BMI, course of the disease and poorly controlled glucose level. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Keywords: type 2 diabetes meltus; osteoporosis; bone mineral density ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "骨质疏松症(osteoporosis,OP)是一种以骨量低下和骨微结构损坏、骨的脆性增加、易发生骨折为特征的全身性骨病。因为其可能导致较高的骨折累积率而成为严重威胁人类健康的公共卫生问题[1-2]。糖尿病(DM)是由于胰岛素分泌或作用缺陷引起的以慢性长期高血糖为特征的一种代谢性疾病3。流行病学调查资料显示[45]，与普通人群相比，糖尿病患者骨质疏松(Diabetic osteoporosis,DO)的发病率和骨质疏松性骨折的危险性明显增加。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "在糖尿病的并发症中，心、脑、肾、眼及皮肤、神经等系统的并发症已被普遍认识，但糖尿病并发骨质疏松症是近几年才开始被医学界认识[。临床观察发现[7-8],糖尿病患者的骨量改变与其临床分型密切相关，对于1型糖尿病，目前比较统一的认识是它可以导致骨量减少，而2型糖尿病对骨量的影响尚缺乏统一定论[9-10]。虽然目前关于2型糖尿病骨质疏松相关风险因素的研究文献已有报道[1I-12],但由于受试对象纳入标准不同常导致研究结论的不一致，部分研究数据甚至因为缺乏相匹配的对照组会产生一定的偏倚。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "基于以上对于2型糖尿病与骨质疏松相关性的认识尚不统一，我们试图通过本组回顾性研究,设置年龄、性别、体质量指数(BMI)相匹配的正常对照组进行比较分析。探讨2型糖尿病合并骨质疏松患者的骨密度(BMD)改变与钙、磷代谢及相关临床指标的相关性，分析2型糖尿病合并骨质疏松较为客观的风险因素，为进一步构建中老年糖尿病骨质疏松患者有效、科学的管理模式以及临床效果评估提供参考。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1资料和方法",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.1研究对象",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "回顾性分析珠江医院骨科及内分泌科住院治疗的2型糖尿病合并骨质疏松患者40例(A组），男22例，女18例，年龄39\\~74岁，平均57.14岁；所有病例均符合WHO糖尿病及骨质疏松诊断标准，并严格遵循相应排除标准。正常对照组相应设定40例(B组)，均为我院同期健康体检者，男性25例，女性15例，年龄41\\~71岁，平均56.98岁。保证所有入组病例信息完整、诊疗过程详实。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2诊断标准",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2.1糖尿病根据WHO(1999年版)糖尿病诊断及分型标准确诊为2型糖尿病：空腹血糖 ${ \\geq } 7 . 0 \\ \\mathrm { m m o l / L }$ ，或随机血糖 ${ \\geq } 1 1 . 1 ~ \\mathrm { m m o l / L }$ ,或口服葡萄糖耐量试验(OGTT)中2 h血浆葡萄糖≥11.1 mmo l/L。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2.2骨质疏松按照WHO推荐的诊断标准即基于双能X线吸收法(DXA)测定骨密度值低于同性别、同种族健康成人的骨峰值不足1个标准差属正常降低；1\\~2.5个标准差之间为骨量低下骨量减少(-1<T值<2.5);降低程度等于和大于2.5个标准差(T值≤-2.5)为骨质疏松。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.3 排除标准",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "有以下情况者予以排除：I型糖尿病、妊娠糖尿病、其他特殊类型糖尿病;排除下列可引起继发性骨质疏松的疾病及严重食管、胃肠道疾病或肝、肾功能不良的患者：甲状腺功能亢进症、甲状旁腺功能亢进症、风湿性关节炎、肾脏疾病等;无糖尿病酮症酸中毒、糖尿病高渗状态及其他急性并发症;无长期卧床史，未服用糖皮质激素等影响骨代谢的药物；有以下情况影响护理干预正常实施者亦排除：严重心血管疾患、老年性痴呆、严重脑出血或脑梗塞、文盲等。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.4相关临床指标测定",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.4.1一般情况记录包括性别、年龄、身高、体质量、体质量指数(BMI) $\\mid =$ 体质量/身高 $^ { 2 } ( \\mathrm { k g } / \\mathrm { m } ^ { 2 } )$ 、病程、既往病史、服药史等。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.4.2生化指标测定采用美国贝克曼库尔特公司生产的BECKMANCX9全自动生化分析仪测定空腹血糖(FBG)、血清钙(S-Ca)、血清磷(S-P)等。同时测量 $2 4 \\mathrm { h }$ 尿钙(U-Ca）尿磷(U-P)等相关指标。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.4.3骨矿密度(BMD)测定所有入组病例均行BMD的测量。检查仪器为美国Norland公司的XR36型双能X线骨密度仪，仪器精确度 $< 1 \\%$ 。选取 $\\scriptstyle \\mathbf { L } _ { 1 \\sim 4 }$ 腰椎分别进行测量，记录并计算腰椎平均BMD值。所有检测值均由配置的软件进行分析。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.5统计学处理",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "用数据均采用SPSS17.0版统计软件处理，计量资料结果用均数 $\\cdot \\pm$ 标准差表示，各组间采用独立样本t检验。应用多元相关分析探讨BMD与患者年龄、糖尿病病程、性别、BMI、血糖、血清钙(S-Ca)、血清磷(S-P)的关系。相关性分析采Pearson相关分析， $P { < } 0 . 0 5$ 为差异具有统计学意义。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2结果",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.1A组与B组临床资料比较(表1) ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "两组资料年龄、性别构成无统计学意义（ $( P { > } 0 . 0 5 )$ ，两组间具有可比性;两组间BMI指数、S-Ca、S-P等相比差异无显著性;而A组FBG、U-Ca、U-P明显高于对照组，两组间比较有显著性差异( $_ { ( P < 0 . 0 5 ) }$ O",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "表1两者间临床资料及生化指标比较",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/26529187b92afc5ee13852f547375f3aaa269b60a21fe7a9bc8d9a7f71595251.jpg",
        "table_caption": [
            "Tab.1 Comparison of clinical data between groups A and B (Mean±SD) "
        ],
        "table_footnote": [
            "$^ { * } P { < } 0 . 0 5$ ；BMI:Body mass index,FBG:Fasting blood glucose,S-Ca: Serum calcium,S-P:Serum phosphate,U-Ca:Urinary calcium,U-P: Urinaryphosphate. "
        ],
        "table_body": "<html><body><table><tr><td>Item</td><td>Group A</td><td>Group B</td></tr><tr><td>n (Male/Female)</td><td>40 (22/18)</td><td>40 (25/15)</td></tr><tr><td>Age (year)</td><td>57.14±8.38</td><td>56.98±7.46</td></tr><tr><td>BMI (kg/m)</td><td>26.76±4.53</td><td>25.13±5.12</td></tr><tr><td>FBG (mmol/L)</td><td>11.10±3.78*</td><td>5.34±0.62</td></tr><tr><td>S-Ca (mmol/L)</td><td>2.23±0.23</td><td>2.14±0.41</td></tr><tr><td>S-P (mmol/L)</td><td>1.07±0.37</td><td>1.06±0.40</td></tr><tr><td>U-Ca (mmol/d)</td><td>4.96±3.56*</td><td>3.51±2.77</td></tr><tr><td>U-P (mmol/d)</td><td>25.03±11.34*</td><td>14.22±6.81</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.2A组与B组BMD比较(表2）A组L1-4腰椎BMD 明显低于B组( $_ { ( P < 0 . 0 5 ) }$ ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.3骨质疏松与临床指标间的相关分析 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "通过BMD与各组临床检测指标的相关分析发现，2型糖尿病骨质疏松患者腰椎BMD与性别相关，并与病程呈负相关，而与BMI、空腹血糖、尿钙、尿磷呈正相关，但与年龄、血钙、血磷无明显相关关系。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "3讨论",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "糖尿病和骨质疏松的关系很复杂[13]。体内和体外的实验都证明[14],在糖尿病的环境下，骨形成和骨微环境发生了整体性的改变。有研究表明2型糖尿病患者骨质疏松发生率明显增高[15-16]。流行病学研究一致认为糖尿病与骨折发生率增加有关[17],而骨折的发生不仅仅取决于骨密度，还与骨的质量、骨成分的改变、骨更新和摔倒的风险以及其他因素有关[18]",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/0c70eb5907ccb9e18e300ae6004a3c6074a84f923cc97b0b5a655c6a7bdbafb8.jpg",
        "table_caption": [
            "表2两者间各部位BMD比较Tab.2 Comparison of BMD between groups Aand B (Mean±SD, $\\scriptstyle n = 4 0$ ）"
        ],
        "table_footnote": [
            "BMD:Bone mineral density. "
        ],
        "table_body": "<html><body><table><tr><td>Group</td><td>L</td><td>L</td><td>L</td><td>L4</td><td>BMD</td></tr><tr><td>A</td><td>0.801±0.110</td><td>0.822±0.104</td><td>0.833±0.137</td><td>0.856±0.201</td><td>0.828±0.135</td></tr><tr><td>B</td><td>0.914±0.099</td><td>0.937±0.127</td><td>0.958±0.154</td><td>0.905±0.187</td><td>0.941±0.141</td></tr><tr><td>t</td><td>2.533</td><td>2.967</td><td>3.112</td><td>3.425</td><td>3.096</td></tr><tr><td>P</td><td>0.012</td><td>0.003</td><td>0.001</td><td>0.001</td><td>0.001</td></tr></table></body></html>",
        "page_idx": 2
    },
    {
        "type": "table",
        "img_path": "images/98a03c99f929b4b73633ede4a6685cc9b3c195f30c7367a7aaa625611cfedfeb.jpg",
        "table_caption": [
            "表3骨质疏松与临床指标间的相关分析 ",
            "Tab.3 Correlation between osteoporosis and the clinical factors "
        ],
        "table_footnote": [
            "All Data compared with BMD.BMI:Body mass index,FBG: Fasting blood glucose. "
        ],
        "table_body": "<html><body><table><tr><td>Items</td><td>1</td><td>P</td></tr><tr><td>Gender</td><td>-0.526</td><td>0.018</td></tr><tr><td>Age (year)</td><td>-0.319</td><td>0.103</td></tr><tr><td>Course of disease (year)</td><td>-0.667</td><td>0.015</td></tr><tr><td>BMI (kg/m²)</td><td>0.129</td><td>0.068</td></tr><tr><td>FBG (mmol/L)</td><td>-0.701</td><td>0.382</td></tr><tr><td>S-Ca (mmol/L)</td><td>0.152</td><td>0.113</td></tr><tr><td>S-P (mmol/L)</td><td>-0.355</td><td>0.746</td></tr><tr><td>U-Ca (mmol/d)</td><td>-0.526</td><td>0.001</td></tr><tr><td>U-P (mmol/d)</td><td>-0.718</td><td>0.001</td></tr></table></body></html>",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "本文通过将糖尿病骨质疏松组与年龄、性别、BMI相匹配的正常对照组比较分析。研究发现，糖尿病合并骨质疏松程度与年龄无关，本研究两组研究对象年龄相互匹配，统计结果亦进一步证实本研究可排除年龄因素所致骨质疏松对结果影响。分析结果发现，糖尿病骨质疏松程度与性别呈一定的相关关系，本组病例中女性患者测得BMD值明显低于男性患者。文献认为[19-20],2型糖尿病男、女患者骨质疏松发病率分别 $3 8 \\%$ 和 $6 5 . 3 \\%$ 女性糖尿病患者的骨质疏松患病率明显高于男性糖尿病患者，其原因为女性的性激素水平较男性下降更多[21]",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "2型糖尿病患者随尿糖排泄增加，尿钙、尿磷排出相应增加，可造成钙磷丢失，血钙有下降趋势，但由于机体反馈调节致使降钙素分泌减少，使破骨细胞活性增高,融骨作用增强,最终血钙、血磷维持正常[22]。有研究认为[16-23],2型糖尿病患者由于渗透性尿钙、尿磷排泄增多，导致继发性PTH及降钙素分泌减少，是导致糖尿病骨质疏松的重要原因之一[13.24]。本组病例也证实，血钙、血磷水平与正常对照组无明显差异;其BMD指数与血钙、血磷也无明显相关关系，而与尿钙、尿磷呈明显负相关关系。本组研究BMD指数与病程成负相关关系也进一步佐证，钙磷持续丢失在一定程度上可加重骨质疏松，导致BMD下降。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "BMI是否为决定T2DM中BMD的主要因素，相关文献报道不一。有研究认为[20.25],2型糖尿病患者BMD与正常人相比无下降，甚至有所增高，可能是2型糖尿病患者具有较高的BMI及发病初期具有高水平的胰岛素。但经BMI纠正后这种差异消失，提示2型糖尿病患者BMD高可部分归因于较高的 $\\mathbf { B M I } _ { \\mathrm { o } }$ 本研究将BMI无差异的正常对照组与2型糖尿病骨质疏松患者匹配分析，结果发现，2型糖尿病骨质疏松组BMD与BMI呈明显正相关关系，证实BMI是决定T2DM中BMD的主要因素之一。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "综上所述，本研究选择了年龄、性别相互匹配的对照组与糖尿病骨质疏松组比较研究，注意骨代谢、内分泌及临床病程等多系统之间的内在联系。研究发现，2型糖尿病骨质疏松BMD与性别、BMI、钙磷代谢等多因素相关。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "参考文献：",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "[1]Palermo A,D'onofrio L,Eastell R,et al. Oral anti-diabetic drugs and fracture risk,cut to the bone:safe or dangerous?A narrative review[J].Osteoporos Int,2015,26(8): 2073-89.   \n[2]Kurra S,Fink DA,Siris ES. Osteoporosis-associated fracture and diabetes[J].Endocrinol Metab Clin North Am,2014,43(1): 233-43.   \n[3]Wongdee K,Charoenphandhu N.Update on type 2 diabetes-related osteoporosis[J].WorldJDiabetes,2015,6(5):673-8.   \n[4]Wild S,Roglic G,Green A,et al.Global prevalence of diabetes: estimates for the year 2OoO and projections for 203o[J].Diabetes Care,2004,27(5):1047-53.   \n[5]Piscitelli P,Neglia C,Vigilanza A,et al.Diabetes and bone: biological and environmental factors [J].Curr Opin Endocrinol Diabetes Obes,2015,22(6): 439-45.   \n[6]Smith LL,Burnet SP,Mcneil JN.Musculoskeletal manifestations of diabetes mellitus[J].BrJ Sports Med,2003,37(1): 30-5.   \n[7]Janghorbani M,Van Dam RM,Willett WC,et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture[J].Am J Epidemiol,2007,166(5): 495-505.   \n[8] Napoli N, Chandran M, Pierroz DD,et al. Mechanisms of diabetes mellitus-induced bone fragility[J].Nat Rev Endocrinol,2016, [Epub ahead of print].   \n[9]Dhaon P, Shah VN.Type 1 diabetes and osteoporosis:A review of literature[J].Indian JEndocrinol Metab,2014,18(2):159-65.   \n[10] Kumar BS,Ravisankar A,Mohan A,et al. Effect of oral hypoglycaemic agents on bone metabolism in patients with type 2 diabetes mellitus & occurrence of osteoporosis[J].Indian J Med Res,2015,141(4): 431-7.   \n[11] Ogata M,Ide R,Takizawa M,et al. Association between basal metabolic function and bone metabolism in postmenopausal women with type 2 diabetes[J].Nutrition,2015,31(11/12):1394-401.   \n[12]Caglayan EK,Engin-Ustun Y, Sari N,et al.Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia[J].JMenopausal Med,2015, 21(1): 36-40.   \n[13]Adil C,Aydin T, Taspinar O,et al.Bone mineral density evaluation of patients with type 2 diabetes mellitus[J].JPhys Ther Sci,2015, 27(1): 179-82.   \n[14] Karimifar M,Pasha MA,Salari A,et al. Evaluation of bone loss in diabetic postmenopausal women[J].JRes Med Sci,2O12,17(11): 1033-8.   \n[15]Aypak C,Turedi O,Bircan MA,et al.Association of haematological parameters with bone mineral density in elderly diabetic women[J].Acta Clin Belg,2015,70(5): 339-44.   \n[16]Rathmann W,Kostev K.Fracture risk in patients with newly diagnosed type 2 diabetes:a. retrospective database analysis in primary care[J].JDiabetes Complications,2015,29(6): 766-70.   \n[17] Yamamoto M. Secondary osteoporosis or secondary contributors to bone loss in fracture.Bone metabolic disorders in patients with diabetes mellitus[J].Clin calcium,2013,23(9):1327-35.   \n[18]Cui RT, Zhou L,Li ZH,et al. Assessment risk of osteoporosis in Chinese people:relationship among body mass index,serum lipid profiles,blood glucose,and bone mineral density[J].Clin Interv Aging,2016,11: 887-95.   \n[19]Lechleitner M,Pils K,Rollr-Wirnsberger R,et al.Diabetes and osteoporosis:pathophysiologicalinteractionsandclinical importance for geriatric patients[J].Z Gerontol Geriatr, 2O13,46(5): 390-7.   \n[20] Leidig-Bruckner G,Grobholz S, Bruckner T,et al.Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus[J].BMC Endocr Disord,2014,14: 33.   \n[21] Issa C, Zantout MS,Azar ST. Osteoporosis in men with diabetes mellitus[J].JOsteoporos,2011,2011: 651867.   \n[22] Rana S,Morya RK,Malik A,et al. Arelationship between vitamin D,parathyroid hormone,calcium levels and lactose intolerance in type 2 diabetic patients and healthy subjects[J].Clin Chim Acta, 2016,462: 174-7.   \n[23] Siddapur PR,Patil AB,Borde VS.Comparison of Bone Mineral Density，T-scores and Serum Zinc between Diabetic and Non Diabetic Postmenopausal Women with Osteoporosis[J].J Lab Physicians,2015,7(1): 43-8.   \n[24]Diab DL,Watts NB. Secondary osteoporosis: differential diagnosis and workup[J]. Clin Obstet Gynecol,2013,56(4): 686-93.   \n[25]Kanazawa I. Diabetes-related osteoporosis[J]. Nihon Rinsho,2015, 73(10): 1718-22. (编辑：经媛) ",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    }
]